Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Drug-Coated Balloon IDE: A Conversation With Lutonix CEO Dennis Wahr

This article was originally published in The Pink Sheet Daily

Executive Summary

Following a four-year effort with FDA, Minneapolis start-up Lutonix recently met its goal to become the first company to gain an investigational device exemption for a drug-coated balloon.

You may also be interested in...



Cook Medical Makes Progress In Peripheral Stent Space

Cook Medical is making advances in the peripheral stent market with the imminent launch of its Formula balloon-expandable renal stent system, and a recent report of two-year data for its PMA-pending Zilver PTX paclitaxel-eluting stent.

TCT In Brief

DES in the leg: Cook Medical's Zilver PTX is the first drug-eluting stent to show clear improvements in treating peripheral artery disease over standard angioplasty and provisional bare-metal stenting in a randomized trial. The paclitaxel-eluting, polymer-free stent met its safety and effectiveness endpoints in Cook's 479-patient pivotal study presented Sept. 24 at the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. Patients with femoropopliteal artery disease randomized to Zilver PTX had an event-free-survival rate (safety) of 90.4% compared to 82.6% in patients randomized to standard angioplasty. On effectiveness, Zilver achieved an 83.1% patency rate. About half of the angioplasties in the control group were judged to be "suboptimal," requiring either a bare-metal stent or Zilver to be placed. Lesions that received "standard care," i.e. either had an "optimal" angioplasty or received a subsequent bare-metal stent, achieved a 67% patency rate. Lesions in the suboptimal group that ultimately received Zilver achieved an 89.9% patency rate compared to 73% in the suboptimal bare metal stent patients. Cook sent the results to FDA this past summer as part of Zilver PTX's pending PMA submission

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS072636

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel